Anti-Inflammatory Effects of Mutant Forms of Secretory Leukocyte Protease Inhibitor
- 1 March 2000
- journal article
- research article
- Published by Elsevier in The American Journal of Pathology
- Vol. 156 (3) , 1033-1039
- https://doi.org/10.1016/s0002-9440(10)64971-1
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences (NIH-GM-29507, PO1-HL-31963)
- National Heart, Lung, and Blood Institute (NIH-GM-29507, PO1-HL-31963)
This publication has 34 references indexed in Scilit:
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13.Journal of Clinical Investigation, 1997
- Requirement and role of C5a in acute lung inflammatory injury in rats.Journal of Clinical Investigation, 1996
- Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cellsInflammation, 1996
- Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.Journal of Clinical Investigation, 1995
- L-Pyroglutamyl-L-prolyl-L-valine-p-nitroanilide, a highly specific substrate for granulocyte elastaseScandinavian Journal of Clinical and Laboratory Investigation, 1983
- A sensitive new substrate for chymotrypsinAnalytical Biochemistry, 1979
- The interaction of α-1-antitrypsin with chymotrypsin, trypsin and elastaseBiochimica et Biophysica Acta (BBA) - Enzymology, 1975
- Isolation and properties of human plasma α-1-proteinase inhibitorBiochemistry, 1974
- Acute Immunologic Pulmonary AlveolitisJournal of Clinical Investigation, 1974